Seleção “o melhor” de 2025

Nas palavras da presidente Gabriela Sousa, nas áreas core da especialidade - Imagiologia, Patologia, Cirurgia, Terapêutica Sistémica - doença precoce e avançada, Radioncologia - esta é uma seleção criteriosa “dos papers de 2025, que podem fazer mudar o estado da arte nos próximos tempos”.

Aceda aos papers apresentados e discutidos no Best of SPS.



Imagiologia e Medicina Nuclear


Comparison of supplemental breast cancer imaging techniques—interim results from the BRAID randomised controlled trial

Gilbert FJ, Payne NR, Allajbeu I, Yit L, Vinnicombe S, Lyburn I, Sharma N, Teh W, James J, Seth A, Suaris T, Aggarwal R, Al-Attar M, Savaridas S, Antoniou A, Pharoah P, Duffy S. The Lancet. 2025 May 31; 405(10493):1935–1944. doi:10.1016/S0140-6736(25)00582-3. PMID: 40412427

  Consultar Artigo

Transforming Breast Imaging: A Narrative Review of Systematic Evidence on Artificial Intelligence in Mammographic Practice

Lastrucci A, Iosca N, Wandael Y, Barra A, Ricci R, Nori Cucchiari J, Forini N, Lepri G, Giansanti D. Diagnostics. 2025;15(17):2197. doi:10.3390/diagnostics15172197

  Consultar Artigo


Patologia


International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories

Rakha EA, Tan PH, van Bockstal MR, Allison KH, Brogi E, Callagy G, Cserni G, Jaffer S, Foschini MP, Gobbi H, Kulka J, Li X, Provenzano E, Shaaban AM, Tse GM, Varga Z, Vincent-Salomon A, Yamaguchi R, Yang W, ElSheikh S, Bhargava R, De Brot M, Canas-Marques R, Marchiò C, Warren MV, van Deurzen CHM, Mir Y, Deb R, Wen H, Ellis IO, Schnitt SJ, Pinder SE, Raymond W, Quinn C, UK National Coordinating Committee of Breast Pathology, the Association of Breast Pathology, the European Working Group for Breast Screening Pathology & the International Society of Breast Pathology. Modern Pathology. 2026;39(1):100925. doi:10.1016/j.modpat.2025.100925

  Consultar Artigo

Genomic characterization of tumor mutational burden-high breast carcinomas

Vougiouklakis T, Vanderbilt C, Rana S, Mohanty A, Pareja F, Brogi E, Schwartz C, Arcila ME, Ladanyi M, Wen HY, Ross DS. NPJ Precision Oncology. 2025 Aug 8;9:277. doi:10.1038/s41698-025-01045-x.

  Consultar Artigo


Cirurgia


Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study

Montagna G, et al.; microNAC Study Group.The Lancet Oncology. 2026;27(1):57-67. doi:10.1016/S1470- 2045(25)00598-4. 40412427

  Consultar Artigo

Effect of re-excision on local recurrence in patients with involved or close margins after upfront breast-conserving surgery: a systematic review and meta-analysis.

Weiner N, Niv Y, Sharon E. World J Surg Oncol. 2025;23:162. doi:10.1186/s12957-025-03811-4

  Consultar Artigo


Terapêutica sistémica: Doença precoce


Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park YH, Fernandez MG, Rubovszky G, Spring L, Im SA, Hui R, Takano T, André F, Yasojima H, Ding Y, Jia L, Karantza V, Tryfonidis K, Bardia A; et al. Nature Medicine. 2025 Jan 21; 31(2):442–448. doi:10.1038/s41591-024-03415-7

  Consultar Artigo

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial

Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim S-B, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen S-C, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau J-F. Annals of Oncology. 2025 Oct 21 (online ahead of print). doi:10.1016/j.annonc.2025.10

  Consultar Artigo


Radioncologia


Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

Mamounas EP, et al.N Engl J Med. 2025;392(21):2113-2124. doi:10.1056/NEJMoa241485910

  Consultar Artigo

Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer

Kunkler, IH et al., 2025. The New England Journal of Medicine, 393(18), pp.1771–1783. doi:10.1056/NEJMoa2412225

  Consultar Artigo


Terapêutica sistémica: Doença avançada


HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Dieras, V et al., 2025. Journal of Clinical Oncology, 43(35), 3600–3610. https://doi.org/10.1200/JCO-25- 02600

  Consultar Artigo

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Bidard F-C, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen S-C, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC, et al. The New England Journal of Medicine. 2025 Jun 1;393(6):569-580. doi:10.1056/NEJMoa2502929.

  Consultar Artigo